Collaboration Between Mid-Atlantic BioTherapeutics and Accelero Biostructures
Mid-Atlantic BioTherapeutics (MABT) and Accelero Biostructures have announced a promising research partnership aimed at discovering new USP30 inhibitors that could address various therapeutic needs. Together, these companies are committed to overcoming significant challenges in the treatment of neurological disorders and other critical medical issues.
Advanced Technologies and Platforms in Use
As part of their collaboration, Accelero will utilize its cutting-edge ABS-OneStep platform, which combines high-throughput protein X-ray crystallography with advanced fragment screening techniques. This state-of-the-art technology acts as a powerful engine for generating hits and is further enhanced by machine learning and artificial intelligence to optimize the drug discovery process.
The Role of Mid-Atlantic BioTherapeutics
MABT will be instrumental in the later stages of drug development. The organization will handle all preclinical testing and spearhead the advanced development of the compounds that emerge from this partnership. This cohesive approach is anticipated to speed up the timeline for bringing effective therapies to market.
The Importance of USP30 in Neurological Disorders
At the center of this research is USP30, a deubiquitinating enzyme that plays a crucial role in regulating cellular processes, particularly those involving mitochondria. By modulating USP30, researchers aim to improve mitophagy, which is essential for removing damaged mitochondria. This process is vital for maintaining cellular health and could significantly impact the fight against oxidative stress associated with various neurological diseases.
Insights from Experts on the Collaboration
David Horn, M.D., CEO of MABT, expressed excitement about the collaboration, noting that targeting USP30 could lead to significant clinical advancements in treating conditions like Alzheimer's and Parkinson's diseases. The team is eager to leverage Accelero's advanced technology to quickly identify new compounds that can positively influence patient outcomes.
In turn, Debanu Das, Ph.D., Co-Founder and CEO of Accelero Biostructures, emphasized the potential of their ABS-OneStep platform. He explained that it has been effectively applied in various contexts and targets, and they are confident it will produce new molecules specifically targeting USP30.
About Mid-Atlantic BioTherapeutics
Mid-Atlantic BioTherapeutics was founded with the mission to combat severe neurological disorders. The company is dedicated to finding solutions for diseases like rabies encephalitis and Alzheimer's. MABT has made notable progress in this field, having received Orphan Drug Designation for its leading programs. Their innovative approach focuses on addressing significant medical needs while exploring new treatment development pathways.
About Accelero Biostructures
Since its inception, Accelero Biostructures has rapidly established itself, leveraging over two decades of expertise in structural genomics and protein biology. The company is committed to providing a comprehensive pipeline of solutions designed to facilitate effective structure-based drug discovery and protein engineering, with ABS-OneStep specifically aimed at enhancing hit generation and streamlining the development of new therapeutics.
Frequently Asked Questions
What is the goal of the collaboration between MABT and Accelero?
The primary goal is to discover novel USP30 inhibitors that target neurological disorders and other medical conditions, enhancing drug development processes.
What technology does Accelero use in drug discovery?
Accelero employs its proprietary ABS-OneStep platform, which is based on high-throughput protein X-ray crystallography and enhanced by machine learning and artificial intelligence.
What role does MABT play in the collaboration?
MABT will conduct all preclinical testing and lead advanced development efforts for the compounds identified during this collaboration.
Why is USP30 an important target?
USP30 is important as it regulates mitophagy, a critical process for removing damaged mitochondria, and its modulation could greatly influence the treatment of various neurological disorders.
When was Mid-Atlantic BioTherapeutics founded?
Mid-Atlantic BioTherapeutics was founded in 2011, focusing on combating severe diseases like rabies encephalitis and Alzheimer's disease.
